Novavax Reports Results of COVID-19-Influenza Vaccine in P-I/II Trial for the Treatment of COVID-19
Shots:
- The P-I/II CIC vaccine trial evaluates NVX-CoV2373 + influenza vaccine candidates & patented saponin-based Matrix-M adjuvant in 642 healthy adults aged 50 to 70yrs. in Australia at 10 sites
- The results showed that the combination vaccine was feasible, well-tolerated & immunogenic. The safety & tolerability profile was consistent with stand-alone NVX-CoV2373 & quadrivalent nanoparticle influenza vaccine reference formulations
- Additionally, protein-based vaccines were formulated with the patented saponin-based Matrix-M adjuvant to boost the immune response & stimulate high levels of neutralizing Abs. The company plans to start the P-II trial & is expected to initiate by the end of 2022
Ref: Novavax | Image: Novavax
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
